Leuk Lymphoma. 2010 Mar;51(3):406-14.

High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma.

Lossos IS, Hosein PJ, Morgensztern D, Coleman F, Escalón MP, Byrne GE Jr, Rosenblatt JD, Walker GR.

Source

Department of Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA. ilossos@med.miami.edu

Abstract

Novel therapeutic approaches are needed in mantle cell lymphoma (MCL). We conducted a phase II study in MCL testing an intensive regimen, R-MACLO-IVAM-T, a modification of the NCI 89-C-41 protocol. Newly diagnosed patients were treated with rituximab, methotrexate, doxorubicin, cyclophosphamide, and vincristine (cycle 1) followed by rituximab, ifosfamide (and mesna), etoposide, and cytarabine (cycle 2). These two cycles were repeated once, and patients achieving complete response (CR) received maintenance thalidomide. Among the 22 patients enrolled, 21 completed two or more cycles and achieved a CR. Three patients relapsed, while 17 are alive and relapse-free after a median follow-up of 37 months (range 19-65 months). Two patients died: one from sepsis during cycle 1 and another at 38 months while in remission from MCL. The progression-free survival at 3 years was 78% (95% CI: 51-91%). These results compare favorably with previously reported outcomes suggesting that durable remissions can be achieved without myeloablative therapy.

Comment in

Leuk Lymphoma. 2010 Mar;51(3):357-9.

PMID:: 20038221; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Supplementary Concepts, Grant Support

Publication Types

MeSH Terms

Substances

Supplementary Concepts

IVAM regimen

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Lymphoma - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Related citations

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. [J Clin Oncol. 2005]
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, et al. J Clin Oncol. 2005 Oct 1; 23(28):7013-23. Epub 2005 Sep 6.
Review Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. [Cancer Chemother Pharmacol. 2002]
Review Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB. Cancer Chemother Pharmacol. 2002 May; 49 Suppl 1:S13-20. Epub 2002 Apr 12.
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. [Eur J Haematol. 2003]
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F. Eur J Haematol. 2003 Apr; 70(4):219-24.
[Therapeutic management of central nervous system lymphomas in a single hematological institute]. [Orv Hetil. 2009]
[Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C. Orv Hetil. 2009 Oct 18; 150(42):1937-44.
Review Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. [Semin Oncol. 2002]
Review Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, et al. Semin Oncol. 2002 Feb; 29(1 Suppl 2):56-69.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

High rate and prolonged duration of complete remissions induced by rituximab, me...
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma.
Leuk Lymphoma. 2010 Mar ;51(3):406-14.

PubMed
Immunotoxin treatment of cancer.
Immunotoxin treatment of cancer.
Annu Rev Med. 2007 ;58:221-37.

PubMed
Importance of protease inhibitor plasma levels in HIV-infected patients treated ...
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.
AIDS. 2000 Jul 7 ;14(10):1333-9.

PubMed
Molecular characterization of the TonB2 protein from the fish pathogen Vibrio an...
Molecular characterization of the TonB2 protein from the fish pathogen Vibrio anguillarum.
Biochem J. 2009 Feb 15 ;418(1):49-59.

PubMed
Neural control of erection.
Neural control of erection.
Physiol Behav. 2004 Nov 15 ;83(2):189-201.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: